Amifostine (WR-2721, Ethyol) is a phosphorylated aminothiol that affords broad cytoprotection from the myelosuppressive effects of antineoplastics. To further characterize its hematopoietic activities, we investigated the effects of amifostine and its dephosphorylated metabolite, WR1065, on the in vitro growth of human bone marrow progenitors. Preincubation exposure to amifostine or WR1065 stimulated the growth of colony-forming units granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM) and erythroid bursts (BFU-E) from bone marrow mononuclear cells in a dose-dependent fashion. Over the concentration range tested (0.1-1000 M), pretreatment with the aminothiols enhanced formation of CFU-GEMM up to five-fold and BFU-E nine-fold, compared to a three-fold increase in myeloid colony recovery. In CD34
Introduction
Low molecular weight thiols are known to exert diverse biological effects, including the modulation of in vitro growth of hematopoietic progenitors. 2-Mercaptoethanol, for example, promotes the formation of multipotent bone marrow progenitors, and serves as a mitogen for human lymphocytes. [1] [2] [3] [4] The aminothiol, vitalethine, augments the formation of erythroid bursts (BFU-E) in response to erythropoietin, whereas the disulfide, cystamine, inhibits lymphocyte proliferation. 3, 5, 6 The mechanism(s) by which thiols exert their trophic effects may be multifactorial, relating in part to intrinsic antioxidant properties, as well as the induction of cytokine elaboration. [7] [8] [9] [10] Recent investigations indicate that cellular redox potential is important in the regulation of early growth response genes involved in S-phase transition, analogous to the molecular events triggered in response to cytokine signaling. [11] [12] [13] [14] [15] The phosphorylated aminothiol, amifostine (WR-2721, Ethyol), protects bone marrow and other normal tissues from radiation and chemotherapy-induced cytotoxicity. [16] [17] [18] [19] [20] [21] fostine is a prodrug that is dephosphorylated to its active form, WR-1065, by membrane-bound alkaline phosphatases. The rapid and preferential accumulation of WR-1065 in bone marrow and other normal tissues is attributed to the higher alkaline phosphatase activity in non-neoplastic cells. [22] [23] [24] Controlled clinical trials have confirmed the effectiveness of this agent in ameliorating the hematologic and organ toxicities of radiation and chemotherapy. 20, 25 Given the broad myeloprotective activity of amifostine in preclinical investigations, this agent might also have intrinsic trophic effects on hematopoietic progenitors. Indeed, early canine studies performed at the Walter Reed Army Research Institute support this notion, reporting the development of reticulocytosis and thrombocytosis, accompanied by a rise in the white blood cell count and hematocrit after single-dose intravenous administration. 26 To further characterize the hemopoietic activities of amifostine, we investigated its effects on the clonogenic growth of hematopoietic progenitors derived from normal bone marrow and CD34
+ mononuclear cell fractions. Our findings indicate that amifostine is a potent stimulant of multipotent and erythroid hematopoietic progenitor formation.
Materials and methods

Cytokines and reagents
Recombinant human kit-ligand (KL, mast cell growth factor) was provided by Immunex Corporation (Seattle, WA, USA). Recombinant human interleukin-3 (IL-3) was a gift of Sandoz Pharmaceuticals (E Hanover, NJ, USA). Interleukin-1␤ (IL-1) and recombinant human erythropoietin (Epo) were purchased from R&D Systems (Minneapolis, MN, USA) and Amgen (Thousand Oaks, CA, USA), respectively. Cytokine concentrations yielding optimal colony recovery were employed as follows: kit-ligand, 20 U/ml; IL-1 and IL-3 100 U/ml; and Epo, 3 U/ml. WR-2721 and WR-1065 were supplied by US Bioscience (W Conshohocken, PA, USA). Glutathione (GSH) was purchased from Sigma Chemicals (St Louis, MO, USA). Thiols were dissolved in phosphate-buffered saline (PBS) and sterilized by filtration. Aliquots were diluted in medium for in vitro studies.
Isolation of CD34
+ cells
Heparinized bone marrow specimens were obtained as excess material from normal allogeneic bone marrow donors after obtaining written informed consent. Low density mononuclear cell fractions were isolated by Ficoll-Hypaque density gradient centrifugation. CD34 + mononuclear cells were isolated using an AIS MicroCELLector flask (Applied Immune Sciences, Santa Clara, CA, USA), with a previously decribed modification to improve CD34 + cell recovery. 27 Progenitors expressing the CD34 antigen were purified using a two-step enrichment procedure that includes elimination of cells attached to covalently immobilized soybean agglutinin (SBA) folllowed by positive selection of CD34 + cells using a polystyrene surface coated with anti-CD34 antibody (ICH3). CD34 MicroCELLector flasks were primed with calcium-and magnesium-free PBS by a 30-min incubation. Bone marrow mononuclear cells were suspended in calcium-magnesium-free PBS containing 0.5% human gammaglobulin at room temperature for 15 min. After incubation, the cell suspension was added to the primed flask containing SBA and gently rocked to ensure cell adsorption. Adherent cells are harvested after 1-h exposure, and cells not adhering to SBA are washed once prior to loading on the CD34 MicroCELLector flask in the presence of 0.5% human gammaglobulin. After a 1-h incubation, the CD34 MicroCELLector flasks are washed up to 10 times with calcium-magnesium-free PBS to ensure elimination of non-adherent CD34-negative cells. Adherence of remaining cells was confirmed by examination under an inverted microscope. Adhering CD34 + SBA-negative cells were detached by 2-h incubation at 37°C in IMDM, containing 10% fetal calf serum (FCS). CD34
+ cells were washed twice and adjusted to a final concentration of 3-10 × 10 3 /ml for colony-forming assays. A CD34 + MNC content ranging from 80 to 90% was confirmed by flow cytometry, and cell viability determined by Trypan Blue exclusion.
Progenitor assays
Growth of colony-forming unit granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM); burst-forming uniterythroid (BFU-E); and colony-forming unit granulocytemacrophage (CFU-GM) was assessed using a modification of techniques previously described. 28 Briefly, low density bone marrow mononuclear cells were exposed to the appropriate thiol or medium for 15 min then washed twice in Iscove's modified Dulbecco's medium (IMDM) before plating. One milliliter suspensions of 2 × 10 5 pretreated mononuclear cells were plated in triplicate in 35 mm Petri dishes in IMDM, 0.8% methylcellulose, 30% fetal calf serum, erythropoietin and 5% phytohemagglutinin-stimulated leukocyte-conditioned medium (PHA-LCM) (Terry Fox Laboratories, Vancouver, BC, Canada) and incubated in a humidified atmosphere with 5% CO 2 at 37°C. Hematopoietic colonies (Ͼ40 cells/colony) and clusters (3-40 cells) were scored after 14 days' incubation using an inverted microscope, and results expressed as mean colony number per 2 × 10 5 plated, and percent of colony growth in control cultures. Assays utilizing recombinant cytokines or CD34
+ selected cells contained 0.8% methylcellulose, Epo and 30% fetal calf serum (FCS) in IMDM. Colony composition was evaluated by pooling randomly selected colonies removed by Pasteur pipette; cells were washed twice, then cytocentrifuged on to glass slides and stained with Wright-Giemsa (Sigma, St Louis, MO, USA) and examined microscopically. Relative maturation of myeloid cells recovered from CFU-GM was ascertained on a 100-cell differential count.
Progenitor cell expansion assay (delta assay)
Expansion of CFU-C in liquid cultures was assessed using a delta assay. Briefly, 2.5 × 10 5 bone marrow mononuclear cells/ml, or 2 × 10 4 CD34 + selected cells/ml were incubated in 20% fetal calf serum and IMDM containing 5 × 10 −5 M 2-mercaptoethanol in 24-well tissue culture plates in a total volume of 4 ml. After 7 days in liquid culture, cells were harvested, washed and counted. Cells were resuspended in medium and cultured in methylcellulose to detect colonyforming cells. Net increase in CFU-C was calculated based on the number of CFU-GM colonies formed in the secondary cultures.
Quantitation of nucleosome generation by ELISA
At selected time intervals, bone marrow MNC incubated in cytokine-deficient medium containing IMDM and 10% FCS, were harvested and cytocentrifuged at 200 g for 10 min. Cell number was recorded and percent viability assessed by Trypan Blue exclusion. Quantitation of apoptotic cell death was determined using an ELISA assay (Boehringer Mannheim, Indianapolis, IN, USA) that measures cytoplasmic DNA-histone complexes generated during nucleosomal DNA fragmentation. The cytoplasmic fraction of lysates from 1 × 10 3 cells were loaded into each well previously coated with antihistone antibody. Cytoplasmic extracts from control and drugtreated cells are equalized on the basis of total cell number. A secondary anti-DNA antibody conjugated to peroxidase is applied, and the ELISA developed with the peroxidase substrate, and the adsorbance at 405 nm was measured using an automated microplate reader (EL311; Bio-Tek Instruments, Winooski, VT, USA). The ELISA provides a quantitative measurement of cytoplasmic DNA-bound histone, rather than free histone or free DNA not specifically released in the cytoplasm during necrotic cell death.
Statistical analysis
Results are expressed as mean colony number ± s.d. from triplicate cultures. Statistical significance was determined using the Student's t-test.
Results
Amifostine augments the growth and size of hematopoietic colonies
To characterize the effects of amifostine on colony formation by bone marrow progenitors, low density bone marrow mononuclear cells (LD-MNC) were incubated for 15 min with varying concentrations of the appropriate thiol to stimulate the brief exposure which occurs in vivo after intravenous administration. LD-MNC were washed three times before plating in methylcellulose with PHA-LCM and erythropoietin as described in the Materials and methods section. Pretreatment with amifostine (WR-2721) or WR-1065 stimulated formation of hematopoietic colonies at clinically relevant concentrations ranging from 0.1 to 1000 M (Figure 1) . Although a sustained level of progenitor stimulation was observed at lower concentrations (0.1-10 M), above this threshold, enhancement in colony-forming capacity was concentration-dependent. Increases in colony number relative to controls were comparable after pretreatment with amifostine or WR-1065. CFU-GEMM and BFU-E were most responsive, yielding colony numbers exceeding 500% (P = 0.004) and 900% (P Ͻ 0.001) of controls, respectively; whereas CFU-GM recovery was Concentration-dependent stimulation of progenitor growth by preincubation treatment with (a) amifostine (WR-2721), (b) WR-1065, and (c) glutathione (GSH). LD-MNC were exposed to thiols for 15 min, washed twice, then plated in triplicate in methylcellulose containing erythropoietin (3 U/ml) and PHA-LCM. Colonies were scored after 14 days incubation and results expressed as percent of colony growth in control cultures. Mean colony numbers in control cultures were: CFU-GEMM, 20; BFU-E, 55; and CFU-GM, 143.
augmented up to 300% (P = 0.02). Further enhancement of colony-forming capacity was not observed after prolonging the duration of pre-incubation exposure to 1, 4, 8 or 24 h (data not shown). Pretreatment with either aminothiol often resulted in the appearance of macroscopic BFU-E and CFU-GEMM, ranging in size from 0.5 to 1.5 mm in maximal diameter (Figure 2 ). Formation of BFU-E and CFU-GEMM was not observed in cultures pretreated with amifostine and plated in the absence of erythropoietin (data not shown), indicating that the stimulatory effect of the aminothiols on early hematopoietic progenitors was erythropoietin-dependent. Glutathione potentiated recovery of BFU-E (P = 0.021) and weakly enhanced CFU-GEMM formation (P = 0.076), however, toxicity was observed at concentrations exceeding 10 M (Figure 1c) .
The effect of amifostine pretreatment on the differentiation of myeloid progenitors was assessed morphologically on cytospin preparations from pooled CFU-GM of three separate experiments after 14 days incubation in LCM and erythropoietin. Although the percentage of myeloblasts did not change (р5%), amifostine treated colonies contained a greater proportion of macrophages (67% ± 8 vs 39% ± 5) and a lower proportion of granulocytes (25% ± 6 vs 51% ± 8).
To determine if the aminothiols potentiate progenitor growth with continuous drug exposure, LD-MNC fractions from six normal donors were plated in methylcellulose in the presence or absence of varying concentrations of amifostine or glutathione. In each of the subjects studied, cultures initiated with amifostine yielded up to 2.5-and 1.5-fold greater recovery of CFU-GEMM and BFU-E, respectively, but did not increase CFU-GM number above controls. A representative experiment is shown in Figure 3 . Potentiation of progenitor growth was not clearly concentration-dependent, but was evident at picomolar concentrations. Toxicity was observed at concentrations exceeding 10 M.
Stimulation of CD34 + cells and cytokine interaction
To investigate the ability of amifostine to modulate colonyforming capacity of CD34 + selected cells and its interaction with recombinant cytokines, progenitor growth was evaluated after pretreatment with amifostine and culture initiation in FCS with erythropoietin, in the presence or absence of cytokine supplementation as indicated in the Methods section. IL-1 and IL-3 had relatively weak colony-promoting activity in the presence of erythropoietin, yielding two-to three-fold greater CFU-GEMM compared to control cultures (Figure 4a ). Although KL increased CFU-GEMM and BFU-E, 16.5-(P = 0.056) and 2.3-fold (P = 0.07) respectively in the experiment illustrated, pretreatment with amifostine at a concentration of (500 M), increased formation of CFU-GEMM 38-fold (P = 0.0037) and BFU-E 3.5-fold (P Ͻ 0.001). CFU-GM recovery after pretreatment with amifostine increased only two-fold. Although amifostine pretreatment increased the number of CFU-GEMM generated in IL-1 and IL-3 initiated cultures, colony yields remained 10-fold less than that observed after amifostine treatment alone. A similar pattern of interaction was observed in cultures initiated in the continuous presence of amifostine (100 nM) (Figure 4b ). Continuous exposure to amifostine increased CFU-GEMM recovery 2.5-fold (P = 0.049), whereas enhancement of IL-1 and IL-3 induced CFU-GEMM and BFU-E formation was less that additive.
Amifostine pretreatment did not augment colony formation in response to KL, and in fact incompletely antagonized the stimulatory effect of the cytokine on CFU-GEMM and BFU-E formation, resulting in lower colony yields than either agent alone (Figure 4a) . In contrast, a synergistic effect on CFU-GEMM formation was observed in cultures initiated in the continuous presence of amifostine and KL (Figure 4b) . The combination yielded 24-fold greater CFU-GEMM compared to controls, whereas cultures initiated with amifostine or KL and erythropoietin augmented colony recovery 2.5-and 16.5-fold, respectively.
Figure 2
Appearance of macroscopic colonies after treatment of CD34 + bone marrow MNC with amifostine. (a) Culture plates represent colony growth in methylcellulose containing erythropoietin and 30% FCS (left), preincubation exposure to amifostine (500 M) (center), or culutres supplemented with recombinant human kit ligand (20 U/ml) (right). (b) BFU-E from a normal donor in control cultures (left) and after amifostine pre-incubation (right) (original magnification × 100).
Figure 3
Effects of continuous amifostine exposure upon hematopoietic progenitor growth. LD-MNC were plated in triplicate in methylcellulose containing erythropoietin (3 U/ml), LCM, and amifostine. Colonies were scored after 14 days incubation and results expressed as percent of colony growth in control cultures.
Expansion of progenitor cells (delta assay)
To determine whether treatment with amifostine alone promotes the survival and ex vivo expansion of more primitive hematopoietic progenitors, generation of myeloid progenitors (CFU-GM) was analyzed after 7-day liquid culture in the presence and absence of amifostine using the delta assay.
Incubation of bone marrow MNC or CD34
+ cell fractions with amifostine in suspension culture increased recovery of secondary colonies Ͼ1.5-fold, but did not reach statistical significance (Table 1) .
Amifostine delays programmed cell death
To determine if amifostine can compensate for the trophic effects of hematopoietic cytokines, its ability to protect LD-MNC against programmed cell death and support progenitor survival with cytokine deprivation was evaluated in short-term Effects of amifostine (WR2721) on colony-formingcapacity of CD34
+ bone marrow MNC. 1 × 10 4 cells were plated in triplicate in methylcellulose cultures containing FCS and erythropoietin. Progenitor growth after amifostine pretreatment (500 M) was compared to cultures initiated with optimal stimulatory concentrations of IL-1 and IL-3 (100 U/ml), and kit ligand (KL, 20 U/ml) after 14 days incubation (a), and in the presence of continuous exposure to amifostine (b). Results are expressed as mean change in colony recovery compared to controls. Mean colony yields in control cultures plated in FCS plus erythropoietin were: CFU-GEMM, 4; BFU-E, 14; and CFU-GM, 71. Generation of CFU-GM was assessed after 7-day suspension culture in IMDM supplemented with 20% FCS ± amifostine as described in the Methods section. Colony number was scored after 14 days incubation in methylcellulose. Values represent mean colony number ± s.d.
liquid culture. Quantitation of nucleosomal DNA fragmentation, cell number and viability were assessed at 24, 48 and 72 h incubation in IMDM and 10% FCS. As shown in Figure 5 , treatment with amifostine retarded DNA fragmentation and cell loss, and promoted cell survival at 24 and 48 h in cytokine-deficient medium.
Discussion
The stimulation of multipotent progenitor growth by amifostine and WR-1065 represents a biological effect of these compounds that is previously unrecognized. The observation that primitive hematopoietic progenitors are most responsive to the aminothiols resembles the potentiating effects of 2-mercaptoethanol, and suggests that the trophic effects of these compounds relates in part to their thiol structure. In agreement with this notion, preincubation exposure to glutathione enhanced formation of BFU-E and CFU-GEMM, albeit to a lesser magnitude and over a more restricted concentration range. Initiation of progenitor cultures in the continuous presence of amifostine was less effective, although promotion of multipotent progenitor formation was demonstrable at picomolar concentrations. This disparity in the growth promoting activity with prolonged drug exposure may be explained by the extracellular metabolism of aminothiols to potentially toxic intermediates. Like the structurally related polyamine, spermidine, the aminothiols are catabolized by amine oxidases present in fetal calf serum to cysteamine, hydrogen per-oxide, and acrolein, the latter of which may deplete intracellular glutathione and possibly antagonize the stimulatory effects of the parent compound. 29 The ability of amifostine to promote the formation of macroscopic colonies and augment recovery of CFU-GEMM and BFU-E resembles the potentiating effects of the recombinant cytokine, kit ligand (KL). However, the magnitude of stimulation of CD34 + progenitors after only brief amifostine exposure exceeds that observed in cultures initiated in the continuous presence of KL and erythropoietin (Figure 4) . Extending the duration of amifostine exposure prior to plating afforded no further enhancement in progenitor stimulation. These findings suggest that amifostine exerts a sustained mitogenic effect in primitive hematopoietic progenitors that results in a profound increase in colony-forming capacity. Interestingly, morphologic examination of myeloid colonies revealed no adverse effect on granulocyte maturation, and apparent promotion of macrophage development. Whether the growth-promoting activity of amifostine results from a direct mitogenic effect and/or recruitment of non-proliferating progenitors may be best addressed in single cell cultures. Nevertheless, the ability of amifostine in the absence of exogenously supplemented cytokines to maintain viability in suspension culture, and enhance formation of myeloid progenitors in secondary cultures suggests that this agent had direct hematopoietic trophic effects. In support of this, amifostine retarded cell loss and delayed apoptosis with cytokine deprivation as measured by nucleosome generation. This ability to abrogate apoptotic signals is a property shared by other organic thiols such as vitalethine, 5 which may contribute to the hematopoietic potentiating effects of these compounds.
The precise mechanism(s) by which amifostine promotes colony formation and cell survival is not clear, but may relate in part to the capacity of low molecular weight thiols to protect cells from oxidative damage and membrane lipid peroxidation, analogous to the antioxidant properties proposed for bcl-2.
7 Cellular glutathione content declines rapidly as an early event in commitment to programmed cell death, coincident with increased transcription of glutathione-S-transferases.
8 By raising intracellular thiol content, aminothiols may abrogate or delay initiation of apoptotic signals. The comparatively greater potentiation of colony recovery by amifostine in CD34 + cells cultivated under conditions of relative cytokine deficiency (ie FCS vs PHA-LCM and erythropoietin) supports this notion. In addition, like the structurally related polyamines, the aminothiols have pleiotropic effects on DNA replication and cell cycle regulation. 30 The symmetrical disulfide intracellular metabolite, WR33278, avidly binds to DNA and nucleoproteins, whereby it alters topoisomerase and thymidine kinase activities, inhibits endonuclease activation, and modulates cell cycle progression. [31] [32] [33] [34] [35] The latter events are believed to result from altered regulation and DNA binding of transcription factors, normally induced in response to cellular stress or oxidative injury. 36 This inherent capacity to modify early response genes or their protein products is shared by other organic thiols such as N-acetyl-L-cysteine and the endogenous redox peptide, thioredoxin. 12, 13 Thioredoxins enhance DNA binding of the redox-sensitive transcription factors, c-fos and c-jun, thereby potentiating response to proliferative signals and providing protection from the cytopathic effects of TNF-␣ and antineoplastics. 11, [37] [38] [39] [40] These events have been linked to the intracellular signaling pathway activated by many of the hematopoietic growth factors, including KL. 14, 15 Whether activation of this effector pathway can be implicated in the trophic effects of amifostine awaits further study.
Although amifostine enhanced IL-1 and IL-3 induced formation of CFU-GEMM and BFU-E when combined either in sequence or concurrently, the degree of potentiation was less than additive. In contrast, interaction with KL demonstrated strict schedule-dependence. In repeated experiments, preincubation exposure to amifostine antagonized the stimulatory effects of KL on multipotent progenitors, whereas synergy was observed when the agents were combined in culture. This apparent contradictory pattern of interaction with KL was not anticipated and remains unexplained. Down-modulation of ckit receptor expression would not alone be expected to account for the rapid and sustained inactivation of progenitor responsiveness to both stimuli. It is possible that amifostine and KL converge upon a common intracelullar signal, whose activation is modulated by divergent upstream events. Indeed, the structural resemblance of WR-1065 and its disulfide metabolite to the polyamines spermidine and spermine, and their recognized overlapping biological properties may explain the observed interaction with KL. Elevation of intracellular polyamine content or forced expression of ornithine decarboxylase, activates mitogen-activated protein (MAP) kinase activity, a proximal target of c-kit receptor signal transduction. 41, 42 Nonetheless, this pattern of interaction suggests that amifostine acts upon early events in the regulation of hematopoiesis, and that its stimulatory effect is not dominant when combined in sequence with isolated cytokines. The precise mechanism of its growth promoting activity awaits further investigation.
In conclusion, our investigations extend the previously recognized hematologic effects of amifostine, [16] [17] [18] [19] [20] [21] and indicate that in addition to its cytoprotective properties, amifostine is a potent stimulant of hematopoietic progenitor growth. The growth promoting activity of amifostine appears to partially overlap, and possibly compete with that of KL. CFU-GEMM and BFU-E are most responsive to amifostine stimulation, however, its interaction with myeloid growth factors such as G-CSF and GM-CSF warrants further investigation. Based upon its in vitro hematopoietic potentiating effects, amifostine has entered clinical investigation as a hematopoietic stimulant in patients with myelodysplastic syndrome. 43 
